{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T05:44:51Z","timestamp":1772603091356,"version":"3.50.1"},"reference-count":34,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T00:00:00Z","timestamp":1690502400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003246","name":"Dutch Research Council","doi-asserted-by":"publisher","award":["09150181910040"],"award-info":[{"award-number":["09150181910040"]}],"id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Multiple drugs targeting the calcitonin gene-related peptide (CGRP) receptor have been developed for the treatment of migraine. Here, the effect of the small-molecule CGRP receptor antagonist zavegepant (0.1 nM\u20131 \u00b5M) on CGRP-induced relaxation in isolated human coronary arteries (HCAs) was investigated. A Schild plot was constructed and a pA2 value was calculated to determine the potency of zavegepant. The potency and Schild plot slopes of atogepant, olcegepant, rimegepant, telcagepant, ubrogepant and zavegepant in HCAs and human middle meningeal arteries (HMMAs), obtained from our earlier studies, were compared. Zavegepant shifted the concentration\u2013response curve to CGRP in HCAs. The corresponding Schild plot slope was not different from unity, resulting in a pA2 value of 9.92 \u00b1 0.24. No potency difference between HCAs and HMMAs was observed. Interestingly, olcegepant, atogepant and rimegepant, with a Schild plot slope &lt; 1 in HCAs, were all &gt;1 log unit more potent in HMMAs than in HCAs, while telcagepant, ubrogepant and zavegepant, with a Schild plot slope not different from unity, showed similar (&lt;1 log difference) potency across both tissues. As a Schild plot slope &lt; 1 may point to the involvement of multiple receptors, it is important to further identify the receptors involved in the relaxation to CGRP in HCAs, which may be used to improve the cardiovascular safety of future antimigraine drugs.<\/jats:p>","DOI":"10.3390\/ph16081075","type":"journal-article","created":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T07:35:24Z","timestamp":1690529724000},"page":"1075","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Blocking the CGRP Receptor: Differences across Human Vascular Beds"],"prefix":"10.3390","volume":"16","author":[{"given":"Tessa","family":"de Vries","sequence":"first","affiliation":[{"name":"Division of Vascular Medicine and Pharmacology, Department of Internal Medicine, Erasmus MC University Medical Center, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9354-715X","authenticated-orcid":false,"given":"Deirdre M.","family":"Boucherie","sequence":"additional","affiliation":[{"name":"Division of Vascular Medicine and Pharmacology, Department of Internal Medicine, Erasmus MC University Medical Center, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoon","family":"van den Bogaerdt","sequence":"additional","affiliation":[{"name":"ETB-BISLIFE, Heart Valve Department, 1940 Beverwijk, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5052-3585","authenticated-orcid":false,"given":"A. H. Jan","family":"Danser","sequence":"additional","affiliation":[{"name":"Division of Vascular Medicine and Pharmacology, Department of Internal Medicine, Erasmus MC University Medical Center, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoinette","family":"MaassenVanDenBrink","sequence":"additional","affiliation":[{"name":"Division of Vascular Medicine and Pharmacology, Department of Internal Medicine, Erasmus MC University Medical Center, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,7,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1161\/HYPERTENSIONAHA.113.02517","article-title":"An ongoing role of alpha-calcitonin gene-related peptide as part of a protective network against hypertension, vascular hypertrophy, and oxidative stress","volume":"63","author":"Smillie","year":"2014","journal-title":"Hypertension"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.tips.2016.06.002","article-title":"Wiping Out CGRP: Potential Cardiovascular Risks","volume":"37","author":"MaassenVanDenBrink","year":"2016","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.pain.2013.07.021","article-title":"Migraine pathophysiology: Anatomy of the trigeminovascular pathway and associated neurological symptoms, CSD, sensitization and modulation of pain","volume":"154","author":"Noseda","year":"2013","journal-title":"Pain"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.pharmthera.2009.09.003","article-title":"The role of CGRP in the pathophysiology of migraine and efficacy of CGRP receptor antagonists as acute antimigraine drugs","volume":"124","author":"Olesen","year":"2009","journal-title":"Pharmacol. Ther."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/ana.410280213","article-title":"Vasoactive peptide release in the extracerebral circulation of humans during migraine headache","volume":"28","author":"Goadsby","year":"1990","journal-title":"Ann. Neurol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/ana.410330109","article-title":"The trigeminovascular system and migraine: Studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats","volume":"33","author":"Goadsby","year":"1993","journal-title":"Ann. Neurol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1046\/j.1468-2982.2002.00310.x","article-title":"CGRP may play a causative role in migraine","volume":"22","author":"Lassen","year":"2002","journal-title":"Cephalalgia Int. J. Headache"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1177\/0333102410368444","article-title":"Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura","volume":"30","author":"Hansen","year":"2010","journal-title":"Cephalalgia Int. J. Headache"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/bph.14075","article-title":"Update on the pharmacology of calcitonin\/CGRP family of peptides: IUPHAR Review 25","volume":"175","author":"Hay","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1159\/000521697","article-title":"Effectiveness of Calcitonin Gene-Related Peptide Receptor Antagonists for Migraine Treatment: A Meta-Analysis","volume":"85","author":"Pak","year":"2022","journal-title":"Eur. Neurol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e01701","DOI":"10.1002\/brb3.1701","article-title":"Gepants for abortive treatment of migraine: A network meta-analysis","volume":"10","author":"Hong","year":"2020","journal-title":"Brain Behav."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S1474-4422(22)00517-8","article-title":"Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: A phase 3, double-blind, randomised, placebo-controlled multicentre trial","volume":"22","author":"Lipton","year":"2023","journal-title":"Lancet Neurol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/head.14439","article-title":"Once-daily oral atogepant for the long-term preventive treatment of migraine: Findings from a multicenter, randomized, open-label, phase 3 trial","volume":"63","author":"Ashina","year":"2023","journal-title":"Headache"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1212\/WNL.0000000000000771","article-title":"Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention","volume":"83","author":"Ho","year":"2014","journal-title":"Neurology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1093\/toxsci\/kfac051","article-title":"Comparing the Liver Safety Profiles of 4 Next-Generation CGRP Receptor Antagonists to the Hepatotoxic CGRP Inhibitor Telcagepant Using Quantitative Systems Toxicology Modeling","volume":"188","author":"Woodhead","year":"2022","journal-title":"Toxicol. Sci."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"03331024231159366","DOI":"10.1177\/03331024231159366","article-title":"Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: A systematic review and network meta-analysis of phase 3 randomised controlled trials","volume":"43","author":"Haghdoost","year":"2023","journal-title":"Cephalalgia Int. J. Headache"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ejphar.2005.11.020","article-title":"Characterisation of CGRP receptors in human and porcine isolated coronary arteries: Evidence for CGRP receptor heterogeneity","volume":"530","author":"Gupta","year":"2006","journal-title":"Eur. J. Pharmacol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.lfs.2006.01.003","article-title":"Characterisation of CGRP receptors in the human isolated middle meningeal artery","volume":"79","author":"Gupta","year":"2006","journal-title":"Life Sci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1124\/jpet.110.165993","article-title":"Characterization of the calcitonin gene-related peptide receptor antagonist telcagepant (MK-0974) in human isolated coronary arteries","volume":"334","author":"Chan","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1177\/0333102410362122","article-title":"Effect of the calcitonin gene-related peptide (CGRP) receptor antagonist telcagepant in human cranial arteries","volume":"30","author":"Edvinsson","year":"2010","journal-title":"Cephalalgia Int. J. Headache"},{"key":"ref_21","first-page":"357","article-title":"Characterisation of the calcitonin gene-related peptide receptor antagonists ubrogepant and atogepant in human isolated coronary, cerebral and middle meningeal arteries","volume":"40","author":"Chan","year":"2019","journal-title":"Cephalalgia Int. J. Headache"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1002\/ana.25831","article-title":"Anti-migraine Calcitonin Gene-Related Peptide Receptor Antagonists Worsen Cerebral Ischemic Outcome in Mice","volume":"88","author":"Mulder","year":"2020","journal-title":"Ann. Neurol."},{"key":"ref_23","unstructured":"Boucherie, D.M., Dammers, R., Vincent, A., Danser, A.H.J., and MaassenVanDenBrink, A. Comparison of gepant effects at therapeutic plasma concentrations: Connecting pharmacodynamics and pharmacokinetics, Cephalalgia, in Press."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1139\/y82-036","article-title":"The Schild regression in the process of receptor classification","volume":"60","author":"Kenakin","year":"1982","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1111\/bph.13445","article-title":"On the different experimental manifestations of two-state \u2018induced-fit\u2019 binding of drugs to their cellular targets","volume":"173","author":"Vauquelin","year":"2016","journal-title":"Br. J. Pharmacol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.3389\/fphar.2020.01240","article-title":"Antagonism of CGRP Signaling by Rimegepant at Two Receptors","volume":"11","author":"Pan","year":"2020","journal-title":"Front. Pharmacol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/acn3.197","article-title":"A second trigeminal CGRP receptor: Function and expression of the AMY1 receptor","volume":"2","author":"Walker","year":"2015","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/acn3.286","article-title":"Comment on \u201cA second trigeminal CGRP receptor: Function and expression of the AMY1 receptor\u201d","volume":"3","author":"Haanes","year":"2016","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S1474-4422(19)30185-1","article-title":"Migraine and the trigeminovascular system-40 years and counting","volume":"18","author":"Ashina","year":"2019","journal-title":"Lancet Neurol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"895476","DOI":"10.3389\/fneur.2022.895476","article-title":"Cerebral Blood Flow and Other Predictors of Responsiveness to Erenumab and Fremanezumab in Migraine-A Real-Life Study","volume":"13","author":"Nowaczewska","year":"2022","journal-title":"Front. Neurol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1136\/jnnp-2021-327992","article-title":"CGRP-mediated trigeminovascular reactivity in migraine patients treated with erenumab","volume":"93","author":"Ferrari","year":"2022","journal-title":"J. Neurol. Neurosurg. Psychiatry."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s10194-021-01295-7","article-title":"Role of CGRP pathway polymorphisms in migraine: A systematic review and impact on CGRP mAbs migraine therapy","volume":"22","author":"Scuteri","year":"2021","journal-title":"J. Headache Pain"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1161\/01.RES.41.1.19","article-title":"Contractile properties of small arterial resistance vessels in spontaneously hypertensive and normotensive rats","volume":"41","author":"Mulvany","year":"1977","journal-title":"Circ. Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1124\/pr.55.4.4","article-title":"International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on terms and symbols in quantitative pharmacology","volume":"55","author":"Neubig","year":"2003","journal-title":"Pharmacol. Rev."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/16\/8\/1075\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:21:16Z","timestamp":1760127676000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/16\/8\/1075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,28]]},"references-count":34,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,8]]}},"alternative-id":["ph16081075"],"URL":"https:\/\/doi.org\/10.3390\/ph16081075","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,28]]}}}